Biomarkers for TBI

Tweedie, D. et al. Elife 9, e55827 (2020)

Traumatic brain injury (TBI) is followed by molecular and cellular events that can cause permanent cell damage and neurodegeneration. No FDA-approved treatment is available for this condition, and biomarkers to quantitatively assess TBI severity are lacking.

Using a murine closed-head weight-drop model of mild TBI that mimics numerous features of the human condition, investigators measured changes in brain tissue proteins related to inflammation at 8, 24, 48, 72, 96 hours, 7, 14 and 30 days after injury. Several proteins including GAS-1 and CXCL16, which are known to modulate neuronal cell death, were identified as potential biomarkers and targets for drug development. Preclinical studies combining protein manipulation and behavioral analysis will be needed to validate these targets.

Author information



Corresponding author

Correspondence to Alexandra Le Bras.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Le Bras, A. Biomarkers for TBI. Lab Anim 49, 290 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing